BBS-Bioactive Bone Substitutes (OHEL:BONEH) EV-to-EBIT : -3.01 (As of May. 25, 2024)

BBS-Bioactive Bone Substitutes EV-to-EBIT Chart

BBS-Bioactive Bone Substitutes Annual Data
	Trend	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBIT		Get a 7-Day Free Trial				-10.56	-12.80	-7.67	-5.32	-3.63

BBS-Bioactive Bone Substitutes Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial											-7.67	-	-5.32	-	-3.63

Competitive Comparison of BBS-Bioactive Bone Substitutes's EV-to-EBIT

For the Medical Devices subindustry, BBS-Bioactive Bone Substitutes's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BBS-Bioactive Bone Substitutes's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BBS-Bioactive Bone Substitutes's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BBS-Bioactive Bone Substitutes's EV-to-EBIT falls into.

BBS-Bioactive Bone Substitutes EV-to-EBIT Calculation

BBS-Bioactive Bone Substitutes's EV-to-EBIT for today is calculated as:

BBS-Bioactive Bone Substitutes's current Enterprise Value is €10.14 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BBS-Bioactive Bone Substitutes's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-3.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BBS-Bioactive Bone Substitutes  (OHEL:BONEH) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

BBS-Bioactive Bone Substitutes's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

BBS-Bioactive Bone Substitutes's Enterprise Value for the quarter that ended in Dec. 2023 was €12.22 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BBS-Bioactive Bone Substitutes's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-3.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BBS-Bioactive Bone Substitutes EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of BBS-Bioactive Bone Substitutes's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

BBS-Bioactive Bone Substitutes (OHEL:BONEH) Business Description